Get Social:

LDL Particle Number (LDL-P) — NMR Advanced Lipid Testing

A more precise way to quantify atherogenic LDL burden when LDL-C doesn’t tell the full story.

Authored by Chris McDermott, APRN — Practicing with autonomous authority in Florida

LDL-P (measured by Nuclear Magnetic Resonance, or NMR) estimates how many LDL particles are circulating—not just how much cholesterol is inside them. Because particle cholesterol content can vary widely (especially with insulin resistance, metabolic syndrome, and during lipid-lowering therapy), LDL-P can help clarify residual cardiovascular risk when standard lipid panels appear “normal.” Learn more about our guided approach within a functional medicine framework.

Understanding LDL-P (NMR)

🧬 What is LDL-P (NMR)?

LDL-P is the concentration of LDL particles in the blood (reported in nmol/L). LDL-C is a cholesterol mass estimate, while LDL-P is a particle count—and cardiovascular risk tends to track more closely with the number of atherogenic particles present.

Key Concepts to Understand About LDL-P

LDL-P often outperforms LDL-C when results are “discordant”

When LDL-C is low but triglycerides are high/HDL is low (common in insulin resistance), LDL particles can be cholesterol-depleted—so LDL-C may underestimate risk while LDL-P remains elevated.

LDL size matters, but particle number is usually the main driver

Small dense LDL is associated with higher risk in many populations, but evidence and consensus statements have emphasized that particle concentration (LDL-P/apoB) often provides more actionable risk information than size alone.

LDL-P can help track “residual risk” on therapy

Some individuals reach LDL-C goals yet continue to carry elevated particle burden. LDL-P (or apoB) can identify that gap and support more individualized risk-reduction planning.

📊 Standard Reference Ranges for (LDL-P)

Reference Range (Adults): (nmol/L)

Desirable: < 1,000
Above desirable: 1,000–1,299
Borderline high: 1,300–1,599
High: 1,600–2,000
Very high: ≥ 2,000

Functional Medicine Cardiovascular Optimization Visit

A root-cause approach to lowering atherogenic particle burden through personalized nutrition, activity, body-composition, and lab-guided therapeutics.

Individualized care • Medically supervised • Lab-guided treatment

⚠️ Abnormal LDL-P Levels: Clinical Implications

Low LDL-P (favorable, in most contexts)

A low LDL-P generally reflects lower atherogenic particle burden and is typically considered cardiometabolically favorable—especially when aligned with apoB, non-HDL-C, triglycerides, and clinical context.

High LDL-P (risk-enhancing)

Higher LDL-P indicates more circulating LDL particles available to enter the arterial wall, promoting plaque biology over time. Persistently elevated LDL-P is commonly seen with insulin resistance/metabolic syndrome, familial lipid patterns, and in some cases despite “controlled” LDL-C.

🧪 Interfering Factors in LDL-P Testing

Physiologic/Clinical Factors
or Assay Interference

Insulin resistance/metabolic syndrome can elevate particle number and increase discordance with LDL-C.
Acute illness/inflammation, recent major dietary change, rapid weight loss, pregnancy/postpartum shifts, and uncontrolled thyroid disease can transiently alter lipoprotein patterns (best interpreted with timing and trend data).

Medications & therapies that can shift LDL-P

Lower LDL-P: statins, ezetimibe, PCSK9 inhibitors, bempedoic acid (often lowers particle burden along with LDL-C).
Mixed/variable effects: niacin and fibrates can shift subclasses and sometimes reduce particle burden, but outcome benefits depend on overall risk profile and contemporary therapy context.
Some drugs (e.g., certain diuretics/beta-blockers, steroids, retinoids) may worsen triglycerides/insulin sensitivity in select patients, indirectly influencing particle patterns.

🔍 Related & Complementary Testing

LDL-P assessment is most informative when evaluated alongside:

Apolipoprotein B (apoB)
ApoB is a practical companion to LDL-P because it estimates the number of atherogenic particles (LDL, VLDL remnants, Lp(a)). When apoB and LDL-P are both elevated, confidence increases that particle burden is truly high; when discordant, context (triglycerides, insulin resistance, therapy status) matters.

🩺 When to Test LDL-P

Consider LDL-P (NMR) when:

LDL-C is “normal” but risk appears higher (family history, metabolic syndrome, insulin resistance, NAFLD, elevated TG/low HDL).
There’s suspected discordance between LDL-C and atherogenic burden.
You want a more granular response assessment to lifestyle or lipid-lowering therapy in intermediate/high-risk contexts.

🧠 Clinical Interpretation Considerations

LDL-P is best used as a risk-refining marker, not a stand-alone diagnosis.

Interpret alongside apoB/non-HDL-C, triglycerides, glycemic markers, blood pressure, smoking status, family history, and (when appropriate) imaging such as CAC.
Testing availability and standardization vary, and major statements have noted uncertainty about incremental value of size measures beyond particle concentration—so LDL-P is typically most helpful in selected patients rather than routine screening.

✅ Clinical Summary

LDL-P (NMR) quantifies atherogenic LDL particle burden and can clarify cardiovascular risk—especially when LDL-C underestimates risk due to particle cholesterol variability (common in insulin resistance and during therapy). When elevated, LDL-P supports intensified, individualized risk-reduction strategies spanning nutrition, exercise, weight/body-composition optimization, insulin-sensitivity support, and (when indicated) targeted lipid-lowering therapy.

📚 Further Reading

1.Beyond Low-Density Lipoprotein Cholesterol: Defining the Role of Low-Density Lipoprotein Heterogeneity in Coronary Artery Disease.

Journal of the American College of Cardiology. 2007. Mudd JO, Borlaug BA, Johnston PV, et al.

2.Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus Conference Report From the American Diabetes Association and the American College of Cardiology Foundation. Journal of the American College of Cardiology. 2008. Brunzell JD, Davidson M, Furberg CD, et al.

3.Association of Small, Dense LDL-cholesterol Concentration and Lipoprotein Particle Characteristics With Coronary Heart Disease: A Systematic Review and Meta-Analysis.

PloS One. 2020. Liou L, Kaptoge S.

4.Small Dense LDL: An Underestimated Driver of Atherosclerosis (Review).

Molecular Medicine Reports. 2025. Bekbossynova M, Saliev T, Ivanova-Razumova T, et al.New

5.Effect of Niacin and Atorvastatin on Lipoprotein Subclasses in Patients With Atherogenic Dyslipidemia. The American Journal of Cardiology. 2001. McKenney JM, McCormick LS, Schaefer EJ, Black DM, Watkins ML.

Advanced Lipid & Cardiometabolic Risk Review

If you’re experiencing metabolic or reproductive symptoms, Understand whether LDL-C and LDL-P are concordant, identify insulin-resistance drivers, and build a targeted plan. Obtain a comprehensive with functional medicine evaluation Intercoastal Health

Personalized care • Clinician-directed • Data-driven treatment

Intercoastal Health

Business Hours
Monday: 9AM – 6PM
Tuesday: 9AM – 6PM
Wednesday: 9AM – 6PM
Thursday: 9AM – 6PM
Friday: 9AM – 6PM
Saturday: Closed
Sunday: Closed

Comprehensive care with a whole person approach, specializing in injury management, wellness, and longevity.

Services

Quick Links

Get in Touch

Phone:
904-799-2531

Email: hello@intercoastalhealth.com

Address:

3874 San Jose Park Drive
Suite 5
Jacksonville, Florida 32217

Disclaimer: The content on this website is for informational purposes only and does not constitute medical advice or replace professional medical care, diagnosis, or treatment. Eligibility for medical treatments will be determined by your healthcare provider, who will exercise discretion regarding your treatment plan. All images are intended for educational purposes only. Statements made on this website have not been evaluated by the Food and Drug Administration. Always consult your healthcare provider before initiating or discontinuing any treatment.